We are live on ! Find out more
PALI icon

Palisade Bio
PALI

8 hedge funds and large institutions have $29.8K invested in Palisade Bio in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

0.53% less ownership

Funds ownership: 0.54% → 0.01% (-0.53%)

27% less funds holding

Funds holding: 11 → 8 (-3)

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

95% less capital invested

Capital invested by funds: $648K → $29.8K (-$618K)

Holders
8
Holders Change
-3
Holders Change %
-27.27%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
2
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
+$5.81K
2
Morgan Stanley
Morgan Stanley
New York
+$2.39K
3
OCM
Orion Capital Management
California
+$704
4
Osaic Holdings
Osaic Holdings
Arizona
+$246

Top Sellers

Rank Fund Capital Flow
1
CH
CVI Holdings
Delaware
-$208K
2
WAM
Warberg Asset Management
Illinois
-$137K
3
VF
Virtu Financial
New York
-$106K
4
TSS
Two Sigma Securities
New York
-$102K
5
Two Sigma Investments
Two Sigma Investments
New York
-$54.1K

PALI Hedge Fund Activity: Q1 2023 in Review

8 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Palisade Bio (PALI) for Q1 2023, worth a combined $29.8K — down 95% from $648K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of PALI and 2 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 2 added.

The largest buyer was Tower Research Capital (TRC), opening a new position worth an estimated $5.81K. The largest seller was CVI Holdings, exiting entirely with an estimated $208K sold.

  • 8 institutional investors held Palisade Bio (PALI) as of Q1 2023, down from 11 in Q4 2022.
  • Funds reported $29.8K of Palisade Bio stock for Q1 2023, down 95% quarter-over-quarter.
  • 2 funds opened new Palisade Bio positions in Q1 2023 and 5 closed out, a net change of -3 holders.
  • The largest Palisade Bio buyer in Q1 2023 was Tower Research Capital (TRC), an estimated $5.81K added.
  • The largest Palisade Bio seller in Q1 2023 was CVI Holdings, an estimated $208K sold.

Based on aggregated 13F filings for Q1 2023.